vs
AIR LEASE CORP（AL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
AIR LEASE CORP的季度营收约是再鼎医药的1.1倍（$140.8M vs $127.1M），AIR LEASE CORP同比增速更快（90.4% vs 17.1%），AIR LEASE CORP自由现金流更多（$342.1M vs $-26.7M），过去两年AIR LEASE CORP的营收复合增速更高（69.6% vs 20.8%）
航空租赁公司（ALC）是2010年成立的美国飞机租赁企业，由史蒂文·F·乌德瓦-哈齐执掌运营。公司直接向波音、空客、巴航工业、ATR采购全新商用飞机，为全球各地航空公司客户提供专业的飞机租赁及融资服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AL vs ZLAB — 直观对比
营收规模更大
AL
是对方的1.1倍
$127.1M
营收增速更快
AL
高出73.3%
17.1%
自由现金流更多
AL
多$368.8M
$-26.7M
两年增速更快
AL
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.8M | $127.1M |
| 净利润 | $180.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 128.5% | — |
| 营收同比 | 90.4% | 17.1% |
| 净利润同比 | 60.2% | — |
| 每股收益（稀释后） | $1.49 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALZLAB
| Q4 25 | $140.8M | $127.1M | ||
| Q3 25 | $44.5M | $115.4M | ||
| Q2 25 | $53.0M | $109.1M | ||
| Q1 25 | $92.9M | $105.7M | ||
| Q4 24 | $74.0M | $108.5M | ||
| Q3 24 | $65.0M | $101.8M | ||
| Q2 24 | $57.8M | $100.1M | ||
| Q1 24 | $49.0M | $87.1M |
净利润ALZLAB
| Q4 25 | $180.9M | — | ||
| Q3 25 | $146.5M | $-36.0M | ||
| Q2 25 | $385.2M | $-40.7M | ||
| Q1 25 | $375.8M | $-48.4M | ||
| Q4 24 | $112.9M | — | ||
| Q3 24 | $104.0M | $-41.7M | ||
| Q2 24 | $102.9M | $-80.3M | ||
| Q1 24 | $107.9M | $-53.5M |
毛利率ALZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率ALZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率ALZLAB
| Q4 25 | 128.5% | — | ||
| Q3 25 | 329.2% | -31.2% | ||
| Q2 25 | 726.9% | -37.3% | ||
| Q1 25 | 404.5% | -45.8% | ||
| Q4 24 | 152.7% | — | ||
| Q3 24 | 160.0% | -40.9% | ||
| Q2 24 | 178.2% | -80.2% | ||
| Q1 24 | 220.2% | -61.4% |
每股收益（稀释后）ALZLAB
| Q4 25 | $1.49 | $-0.05 | ||
| Q3 25 | $1.21 | $-0.03 | ||
| Q2 25 | $3.33 | $-0.04 | ||
| Q1 25 | $3.26 | $-0.04 | ||
| Q4 24 | $0.83 | $-0.09 | ||
| Q3 24 | $0.82 | $-0.04 | ||
| Q2 24 | $0.81 | $-0.08 | ||
| Q1 24 | $0.87 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.4M | $689.6M |
| 总债务越低越好 | $19.7B | — |
| 股东权益账面价值 | $8.5B | $715.5M |
| 总资产 | $32.9B | $1.2B |
| 负债/权益比越低杠杆越低 | 2.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALZLAB
| Q4 25 | $466.4M | $689.6M | ||
| Q3 25 | $452.2M | $717.2M | ||
| Q2 25 | $454.8M | $732.2M | ||
| Q1 25 | $456.6M | $757.3M | ||
| Q4 24 | $472.6M | $779.7M | ||
| Q3 24 | $460.8M | $616.1M | ||
| Q2 24 | $454.1M | $630.0M | ||
| Q1 24 | $554.4M | $650.8M |
总债务ALZLAB
| Q4 25 | $19.7B | — | ||
| Q3 25 | $20.2B | — | ||
| Q2 25 | $20.3B | — | ||
| Q1 25 | $19.9B | — | ||
| Q4 24 | $20.2B | — | ||
| Q3 24 | $20.2B | — | ||
| Q2 24 | $19.7B | — | ||
| Q1 24 | $19.5B | — |
股东权益ALZLAB
| Q4 25 | $8.5B | $715.5M | ||
| Q3 25 | $8.3B | $759.9M | ||
| Q2 25 | $8.2B | $791.7M | ||
| Q1 25 | $7.9B | $810.8M | ||
| Q4 24 | $7.5B | $840.9M | ||
| Q3 24 | $7.7B | $667.7M | ||
| Q2 24 | $7.3B | $704.2M | ||
| Q1 24 | $7.2B | $762.2M |
总资产ALZLAB
| Q4 25 | $32.9B | $1.2B | ||
| Q3 25 | $33.4B | $1.2B | ||
| Q2 25 | $33.3B | $1.2B | ||
| Q1 25 | $32.4B | $1.2B | ||
| Q4 24 | $32.3B | $1.2B | ||
| Q3 24 | $32.2B | $985.3M | ||
| Q2 24 | $31.0B | $987.4M | ||
| Q1 24 | $30.9B | $988.4M |
负债/权益比ALZLAB
| Q4 25 | 2.33× | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.68× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | 2.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $414.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $342.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 242.9% | -21.0% |
| 资本支出强度资本支出/营收 | 51.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.29× | — |
| 过去12个月自由现金流最近4个季度 | $1.5B | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ALZLAB
| Q4 25 | $414.1M | $-26.0M | ||
| Q3 25 | $458.6M | $-32.0M | ||
| Q2 25 | $473.6M | $-31.0M | ||
| Q1 25 | $388.3M | $-61.7M | ||
| Q4 24 | $430.0M | $-55.8M | ||
| Q3 24 | $461.9M | $-26.8M | ||
| Q2 24 | $413.8M | $-42.2M | ||
| Q1 24 | $371.3M | $-90.1M |
自由现金流ALZLAB
| Q4 25 | $342.1M | $-26.7M | ||
| Q3 25 | $412.3M | $-35.0M | ||
| Q2 25 | $427.1M | $-33.9M | ||
| Q1 25 | $315.5M | $-63.2M | ||
| Q4 24 | $326.8M | $-58.4M | ||
| Q3 24 | $369.8M | $-28.2M | ||
| Q2 24 | $346.4M | $-42.9M | ||
| Q1 24 | $246.8M | $-91.1M |
自由现金流率ALZLAB
| Q4 25 | 242.9% | -21.0% | ||
| Q3 25 | 926.6% | -30.4% | ||
| Q2 25 | 806.0% | -31.1% | ||
| Q1 25 | 339.5% | -59.9% | ||
| Q4 24 | 441.8% | -53.8% | ||
| Q3 24 | 569.1% | -27.7% | ||
| Q2 24 | 599.5% | -42.9% | ||
| Q1 24 | 503.8% | -104.5% |
资本支出强度ALZLAB
| Q4 25 | 51.1% | 0.5% | ||
| Q3 25 | 104.1% | 2.6% | ||
| Q2 25 | 87.8% | 2.6% | ||
| Q1 25 | 78.4% | 1.5% | ||
| Q4 24 | 139.6% | 2.4% | ||
| Q3 24 | 141.7% | 1.3% | ||
| Q2 24 | 116.7% | 0.7% | ||
| Q1 24 | 254.3% | 1.1% |
现金转化率ALZLAB
| Q4 25 | 2.29× | — | ||
| Q3 25 | 3.13× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 3.81× | — | ||
| Q3 24 | 4.44× | — | ||
| Q2 24 | 4.02× | — | ||
| Q1 24 | 3.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AL
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
